Foosung (093370) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
23 Feb, 2026Executive summary
Q1 2025 consolidated sales reached ₩107.1 billion, down 1.3% year-over-year due to global economic slowdown and weaker demand in downstream industries, especially for battery materials and semiconductor specialty gases.
Operating loss was ₩0.1 billion, with a net loss of ₩1.9 billion attributable to the parent, reflecting margin pressure and lower sales.
The company maintains a leading position in fluorochemical products and chemical plant equipment, with ongoing investments in capacity and R&D.
Financial highlights
Q1 2025 revenue: ₩107.1 billion (down 1.3% YoY); operating loss: ₩0.1 billion; net loss: ₩1.9 billion.
Gross margin declined due to higher raw material costs and lower utilization rates.
Cash and equivalents at quarter-end: ₩83.8 billion; total assets: ₩860.7 billion; equity: ₩365.7 billion.
Q1 2025 R&D expenditure: ₩2.0 billion (3.2% of sales).
Outlook and guidance
Management expects continued market volatility due to global economic and geopolitical uncertainties.
Focus remains on expanding global market share in battery materials and specialty gases, and on cost control.
Ongoing investments in new production lines for LiPF6 and semiconductor gases to support future growth.
Latest events from Foosung
- Revenue up 7.7% to KRW 471.6B, operating profit rebounds, debt ratio improves.093370
Q4 202518 Mar 2026 - H1 2024 saw revenue drop 24.8% and an operating loss, but net profit returned after capital raising.093370
Q2 202423 Feb 2026 - Revenue down 37% YoY, net loss narrows, cash up after rights offering and capacity expansion.093370
Q3 202423 Feb 2026 - 2024 saw a 16% revenue drop and net loss amid weak battery and semiconductor demand.093370
Q4 202423 Feb 2026 - H1 2025 revenue rose 4.9% and operating profit turned positive, led by battery and gas segments.093370
Q2 202523 Feb 2026 - Revenue up 7.6% YoY, operating income positive, net loss narrowed, and capital raised for growth.093370
Q3 202523 Feb 2026